Clinical Trial News
This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.
Get news by email or subscribe to our news feeds.
Synergy Pharmaceuticals Presents Plecanatide Results From a Large Multicenter Clinical Study at Late-Breaking Abstract Session During Digestive Disease Week 2013
Posted yesterday in Clinical Trials
NEW YORK, May 21, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat patients with gastrointestinal disorders and diseases, today presented positive safety and efficacy results from its large multicenter trial of plecanatide in patients with chronic idiopathic constipation (CIC) at Digestive Disease Week (DDW) in Orlando, FL. The data were...
Read more...How Safe Are Prescription Drug Doses if Patients in Clinical Trials Did Not Take the Full Dose?
Posted yesterday in Clinical Trials
'How Safe Are Prescription Drug Doses if Patients in Clinical Trials Did Not Take the Full Dose?' Asks Consumer Health Information Corporation Unexpected drug toxicities occurring years after prescription drug approval MCLEAN, Va., May 21, 2013 /PRNewswire/ -- In the last ten years, many people have developed unexpected toxicities from prescription drugs that had been on the market for several...
Read more...Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma
Posted yesterday in Clinical Trials
Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine Phase 2a study of the IL-4R alpha inhibitor, dupilumab, demonstrated 87% reduction in risk of asthma exacerbations in moderate-to-severe asthma patients with elevated eosinophils PARIS and TARRYTOWN, N.Y., May 21, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and...
Read more...New Data Reinforces Strength of Novartis Once-Daily COPD Portfolio
Posted yesterday in Clinical Trials
New data reinforces strength of Novartis once-daily COPD portfolio in improving lung function, shortness of breath and reducing rate of exacerbations • BLAZE study showed once-daily QVA149 significantly improved patient self-reported shortness of breath and lung function compared to placebo and tiotropium 18 mcg[1] • SPARK results showed that QVA149 significantly reduced rate of all...
Read more...Janssen Phase III Hepatitis C Drug Shows Sustained Virologic Response
Posted yesterday in Clinical Trials
Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients ORLANDO, Fla., May 21, 2013 /PRNewswire/ -- Janssen R&D Ireland (Janssen) today announced primary efficacy and safety results from the global Phase 3 PROMISE study demonstrating...
Read more...Synageva's Sebelipase Alfa Receives Breakthrough Therapy Designation
Posted yesterday in Clinical Trials
Synageva's Sebelipase Alfa Receives Breakthrough Therapy Designation for Early Onset LAL Deficiency from the U.S. Food and Drug Administration LEXINGTON, Mass.--(BUSINESS WIRE)-- Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough...
Read more...Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Due to Futility
Posted yesterday in Clinical Trials
Pfizer to Continue Evaluation of Inotuzumab Ozogamicin in Other Hematologic Malignancies NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today the discontinuation of a Phase 3 randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL) who...
Read more...Novozymes Biopharma’s recombinant human albumin helps innovative dry eye therapy move into clinical trials
Posted 2 days ago in Clinical Trials
A novel ophthalmic solution from R-Tech Ueno (Tokyo, Japan) made using Novozymes Biopharma’s recombinant human albumin has recently obtained FDA approval to undergo Phase I/II clinical trials in the United States. NOTTINGHAM, UK – May 20, 2013 – Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, today announced that an ophthalmic solution made using its recombinant...
Read more...Asmacure Highlights Four Presentations on Novel Pulmonary Development Compound ASM-024 Presented at American Thoracic Society 2013 International Conference
Posted 2 days ago in Clinical Trials
--Demonstration of ASM-024 adjunctive benefit with current treatments in pre-clinical asthma models-- QUEBEC CITY, May 20, 2013 /PRNewswire/ -- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of novel, proprietary compounds that target cholinergic receptors for the treatment of pulmonary diseases, today announced presentations of four studies of ASM-024, Asmacure's...
Read more...Study: Few Patient-Reported Outcomes Are Included in Diabetes Clinical Trials
Posted 2 days ago in Clinical Trials
Despite Rising Pharmaceutical Industry Interest in Real World Outcomes, Few Patient-Reported Outcomes Are Included in Diabetes Clinical Trials According to a Context Matters/Pfizer Study NEW ORLEANS, May 20, 2013 (GLOBE NEWSWIRE) -- Despite rising interest in real world outcomes, a recent study performed by Context Matters and Pfizer demonstrates that less than ten percent of diabetes clinical...
Read more...Neuralstem ALS Trial Principal Investigator Presents Phase I Data
Posted 2 days ago in Clinical Trials
Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania Data Shows, Early Stem Cell Transplantation Could Slow Progression Or Even Improve Patient's Condition in Some Forms of ALS ROCKVILLE, Md., May 20, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported that Eva Feldman, MD, PhD, principal...
Read more...Sangamo BioSciences Presents New Data From In Vivo Protein Replacement Platform For Development Of ZFP Therapeutics® For Monogenic Diseases
Posted 2 days ago in Clinical Trials
Production of Therapeutically Relevant Levels of Clotting Factor VIII Further Demonstrates Breadth and Leverage of this Novel Approach to Monogenic Diseases Presentations at ASGCT Annual Meeting Highlight Broad Applicability of ZFP Technology RICHMOND, Calif., May 20, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of new data demonstrating the successful...
Read more...TRACON Pharmaceuticals Announces TRC105 Clinical Trials, Abstract Presentations at 2013 ASCO Annual Meeting
Posted 2 days ago in Clinical Trials
SAN DIEGO, May 20, 2013 /PRNewswire/ -- TRACON Pharmaceuticals, a biopharmaceutical company that develops targeted therapies for oncology and ophthalmology, today announced multiple clinical investigations for TRC105 and the presentation of two abstracts at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO), held May 31 to June 4 in Chicago. TRC105, a novel monoclonal...
Read more...Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes
Posted 2 days ago in Clinical Trials
BOSTON, May 20, 2013 /PRNewswire/ -- Rhythm announced today the results of a second Phase 1b clinical trial of RM-131, the company's novel ghrelin agonist for the treatment of diabetic gastroparesis in type 1 diabetic patients. The trial demonstrated that RM-131 significantly accelerates early gastric emptying and reduces upper gastrointestinal (GI) symptoms in type 1 diabetic patients with...
Read more...Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S.
Posted 2 days ago in Clinical Trials
-- Despite high prevalence of symptoms, rate of gastroparesis diagnosis is low among those with type 2 diabetes -- BOSTON, May 20, 2013 /PRNewswire/ -- Rhythm announced today the presentation of results from a new epidemiology study demonstrating a higher prevalence of gastroparesis symptoms among diabetic patients in the U.S. than previously recognized. Prevalence of these symptoms is high...
Read more...Cempra Presents Post-Phase II Analysis of Solithromycin's Efficacy and Safety
Posted 2 days ago in Clinical Trials
Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) Solithromycin demonstrated enhanced anti-inflammatory response, in vitro Data presented at the American Thoracic Society International Conference CHAPEL HILL, N.C., May 20, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage...
Read more...Intercept Pharmaceuticals Announces Positive Initial Results from Chronic Bile Acid Diarrhea Trial
Posted 2 days ago in Clinical Trials
Intercept Pharmaceuticals Announces Positive Initial Results from Ongoing Phase 2a Trial in Chronic Bile Acid Diarrhea NEW YORK, May 20, 2013 /PRNewswire/ -- Intercept Pharmaceuticals, Inc. ("Intercept", NASDAQ: ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, today announced positive initial...
Read more...Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
Posted 2 days ago in Clinical Trials
SAN DIEGO, May 20, 2013 /PRNewswire/ -- Enrollment of patients with Type 2 diabetes is underway in Elcelyx Therapeutics' Phase 2b dose-finding clinical trial of product candidate NewMet™, a delayed-release formulation of generic metformin, the foundational treatment for Type 2 diabetes. Elcelyx expects to complete enrollment of 240 patients in the multicenter U.S. program in June. Results of the...
Read more...XenoPort Reports Top-Line Results of Phase 3 Trial of Arbaclofen Placarbil for Spasticity in Multiple Sclerosis Patients
Posted 2 days ago in Clinical Trials
SANTA CLARA, Calif.--(BUSINESS WIRE)-- XenoPort, Inc. (Nasdaq: XNPT) announced today top-line results from its pivotal Phase 3 clinical trial of arbaclofen placarbil (AP) for the treatment of patients with spasticity due to multiple sclerosis (MS). The trial was unsuccessful in demonstrating that AP provided statistically significant improvement relative to placebo in the co-primary endpoints of...
Read more...Healthcare Providers at Lilly Play Important Role in Helping Patients
Posted 2 days ago in Clinical Trials
From Research Labs to Doctors' Offices, Health Care Providers at Lilly Play Important Role in Bringing New and Innovative Medicines to Patients Video shows how those from the medical field bring patient care experience to pharmaceutical career INDIANAPOLIS, May 20, 2013 /PRNewswire/ -- The many health care providers working at Eli Lilly and Company (NYSE:LLY) − including doctors, nurses, and...
Read more...
